CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for PROLOR Biotech Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

PROLOR Biotech Inc
202 N CARSON ST
CARSON CITY, NV  89701  United States Ticker: PBTHPBTH
This company was Merged or Acquired on 8/29/2013.
This company ceased filing statements with the SEC on 9/26/2013.
This is a Subsidiary, click here for the Parent Company
Business Summary
Prolor Biotech Inc. (Prolor) is a development-stage biopharmaceutical company. The Company develops longer-acting versions of therapeutic proteins. Prolor is using the carboxyl terminal peptide technology. The Company’s product development program is focused on extending the life span of Human Growth Hormone, Factor IX, Anti-Obesity Peptide Oxyntomodulin, Factor VIIa, Interferon B and Erythropoietin and Atherosclerosis and rheumatoid arthritis long-acting therapies. Human Growth Hormone is used for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone. In March 2012, the Company initiated a Phase II trial of hGH-CTP in children with growth hormone deficiency. Factor IX Factor IX is offered to Hemophilia B patients. In February 2012, the Company completed the study hemophilia drug Factor VIIa in hemophilic mice and was designed to measure the potential in survival rates and in vivo recovery of Factor VIIa-CTP.
(Source: ARS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/201312/31/2012YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
7330 Mailing, reproduction, commercial art and photography, and stenography
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Director Shai A.Novik 55 5/9/2007 5/9/2007
Chief Executive Officer, Director AbrahamHavron 73 5/9/2007 5/9/2007
Chief Operating Officer of ModigeneTech EyalFima 1/1/2010 11/1/2005
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Modigene Inc.
Modigene Inc.
ModigeneTech Ltd.
PBTH
PROLOR Biotech, Inc.
Prolor Ltd.

General Information
Number of Employees: 25 (As of 12/31/2012)
Outstanding Shares: 63,854,883 (As of 8/8/2013)
Shareholders: 117
Stock Exchange: TLV
Federal Tax Id: 200854033
Email Address: info@prolor-biotech.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, August 30, 2023